Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy

FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocyte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2024-07, Vol.30 (7), p.1795-1796
1. Verfasser:	Healey, Natalie
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedicine Cancer immunotherapy Cancer Research Cervical cancer Immunotherapy Infectious Diseases Lung cancer Lymphocytes Melanoma Metabolic Diseases Molecular Medicine Neurosciences News Solid tumors Tumor-infiltrating lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more. Image credit: Denis Pobytov / DigitalVision Vectors / Getty
ISSN:	1078-8956 1546-170X 1546-170X
DOI:	10.1038/d41591-024-00040-2